Literature DB >> 11064183

Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.

C B Eap1, M Bourquin, J Martin, J Spagnoli, S Livoti, K Powell, P Baumann, J Déglon.   

Abstract

Methadone is a 50:50 mixture of two enantiomers and (R)-methadone accounts for the majority of its opioid effect. The aim of this study was to determine whether a blood concentration of (R)-methadone can be associated with therapeutic response in addict patients in methadone maintenance treatment. Trough plasma concentrations of (R)-, (S)- and (R,S)-methadone were measured in 180 patients in maintenance treatment. Therapeutic response was defined by the absence of illicit opiate or cocaine in urine samples collected during a 2-month period prior to blood sampling. A large interindividual variability of (R)-methadone concentration-to-dose-to-weight ratios was found (mean, S.D., median, range: 112, 54, 100, 19-316 ng x kg/ml x mg). With regard to the consumption of illicit opiate (but not of cocaine), a therapeutic response was associated with (R)- (at 250 ng/ml) and (R,S)-methadone (at 400 ng/ml) but not with (S)-methadone concentrations. A higher specificity was calculated for (R)- than for (R,S)-methadone, as the number of non-responders above this threshold divided by the total number of non-responders was higher for (R,S)-methadone (19%) than for (R)-methadone (7%). The results support the use of therapeutic drug monitoring of (R)-methadone in cases of continued intake of illicit opiates. Due to the variability of methadone concentration-to-dose-to-weight ratios, theoretical doses of racemic methadone could be as small as 55 mg/day and as large as 921 mg/day to produce a plasma (R)-methadone concentration of 250 ng/ml in a 70-kg patient. This demonstrates the importance of individualizing methadone treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064183     DOI: 10.1016/s0376-8716(00)00121-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  27 in total

1.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

4.  Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Authors:  Debra L Bogen; James M Perel; Joseph C Helsel; Barbara H Hanusa; Matthew Thompson; Katherine L Wisner
Journal:  Breastfeed Med       Date:  2011-02-24       Impact factor: 1.817

Review 5.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

6.  Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes.

Authors:  Ana de Castro; Hendreé E Jones; Rolley E Johnson; Teresa R Gray; Diaa M Shakleya; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-08       Impact factor: 3.681

Review 7.  Clinical pharmacokinetics of darunavir.

Authors:  Michael Rittweger; Keikawus Arastéh
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Route of administration influences substitution patterns in rats trained to discriminate methadone vs. vehicle.

Authors:  Robert E Vann; Laura E Wise; Stephen A Varvel; Scott D Philibin; D Matthew Walentiny; Joseph H Porter
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

9.  Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level.

Authors:  Olga Rass; Bethea A Kleykamp; Ryan G Vandrey; George E Bigelow; Jeannie-Marie Leoutsakos; Maxine L Stitzer; Eric C Strain; Marc L Copersino; Miriam Z Mintzer
Journal:  Exp Clin Psychopharmacol       Date:  2014-02-17       Impact factor: 3.157

10.  Pharmacokinetic interaction between telaprevir and methadone.

Authors:  Rolf van Heeswijk; Peter Verboven; Ann Vandevoorde; Petra Vinck; Jan Snoeys; Griet Boogaerts; Els De Paepe; Rodica Van Solingen-Ristea; James Witek; Varun Garg
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.